Drug intelligence / Profile preview

ITF3912

Development stage: Preclinical
Lead developer: Italfarmaco
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides

Overview

ITF3912 is a peptide-drug conjugate (PDC) being developed by Italfarmaco for the treatment of solid tumors. As a PDC, it is designed to selectively deliver a cytotoxic payload to tumor cells by utilizing a peptide ligand that targets specific receptors or proteins overexpressed on the surface of cancer cells. This targeted approach aims to enhance the therapeutic index of the cytotoxic agent while minimizing systemic toxicity. Currently, the drug is in the IND-enabling stage of development, and its specific molecular target and payload components have not been publicly disclosed.

Targets

SSTR2 (Somatostatin receptor type 2)

Beyond the preview

Go deeper on ITF3912.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITF3912.

Explore the full profile